GE Healthcare's illustra ExoStar kit is designed to provide a high-performance and cost-effective product for the enzymatic removal of unincorporated primers and nucleotides from PCR and sequencing reactions.
The kit enables efficient primer digestion with no degradation of target PCR
products, allowing almost 100% yield of the desired PCR products.
The PCR clean-up product contains two enzymes that have been expressly
designed to work together, with one tube of exonuclease 1 at a concentration
of 10U µl-1 and one tube of illustra alkaline phosphatase at a concentration
of 1U µl-1.
GE Healthcare patented the original enzymatic approach for PCR and sequencing
clean-up reactions, with the new ExoStar now providing an advanced
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.